Employing “FDAlabel” Database to Extract Pharmacogenomics Information from FDA Drug Labeling to Advance the Study of Precision Medicine by Uber, Ryley B. et al.
Cedarville University
DigitalCommons@Cedarville
The Research and Scholarship Symposium The 2017 Symposium
Apr 12th, 11:00 AM - 2:00 PM
Employing “FDAlabel” Database to Extract
Pharmacogenomics Information from FDA Drug
Labeling to Advance the Study of Precision
Medicine
Ryley B. Uber
Cedarville University, ryleyuber@cedarville.edu
Hong Fang
National Center for Toxicological Research
Zhichao Liu
National Center for Toxicological Research
Joshua Xu
National Center for Toxicological Research
Shraddha Thakkar
National Center for Toxicological Research
See next page for additional authors
Follow this and additional works at: http://digitalcommons.cedarville.edu/
research_scholarship_symposium
Part of the Other Pharmacy and Pharmaceutical Sciences Commons, Pharmaceutics and Drug
Design Commons, and the Pharmacy Administration, Policy and Regulation Commons
This Poster is brought to you for free and open access by
DigitalCommons@Cedarville, a service of the Centennial Library. It has
been accepted for inclusion in The Research and Scholarship Symposium
by an authorized administrator of DigitalCommons@Cedarville. For more
information, please contact digitalcommons@cedarville.edu.
Uber, Ryley B.; Fang, Hong; Liu, Zhichao; Xu, Joshua; Thakkar, Shraddha; Amur, Shashi; Mummaneni, Padmaja; Chen, Minjun;
Ning, Baitang; Harris, Steve; Zhou, Guangxu; Wu, Leihong; Howard, Paul; and Tong, Weida, "Employing “FDAlabel” Database to
Extract Pharmacogenomics Information from FDA Drug Labeling to Advance the Study of Precision Medicine" (2017). The Research
and Scholarship Symposium. 21.
http://digitalcommons.cedarville.edu/research_scholarship_symposium/2017/poster_presentations/21
Presenters
Ryley B. Uber, Hong Fang, Zhichao Liu, Joshua Xu, Shraddha Thakkar, Shashi Amur, Padmaja Mummaneni,
Minjun Chen, Baitang Ning, Steve Harris, Guangxu Zhou, Leihong Wu, Paul Howard, and Weida Tong
This poster is available at DigitalCommons@Cedarville: http://digitalcommons.cedarville.edu/research_scholarship_symposium/
2017/poster_presentations/21
Employing “FDAlabel” Database to Extract Pharmacogenomics Information from  
FDA Drug Labeling to Advance the Study of Precision Medicine  
 
Pharmacogenomics (PGx) focuses on how genomics and genetic variants (inherited and acquired) 
affect drug response. A better understanding of the association between genetic markers and individual 
phenotypes may improve therapy by enhancing drug efficacy, safety, and advance precision medicine. 
The FDALabel database (https://rm2.scinet.fda.gov/druglabel/#simsearch-0) was developed from the 
FDA's Structured Product Labeling (SPL) repository to allow users to perform full-text and customizable 
searches of the labeling section {e.g. Boxed Warning, Warning and Precautions, Adverse Reaction (AR) 
sections}. In this study, 48 known biomarkers were used to query PGx relevant contents from the 
FDALabel database, including Indication, Clinical Pharmacology, Clinical Studies, and Use in Specific 
Populations. As a result, we identified 162 drugs out of 1129 small molecule drugs with PGx biomarker 
information. Furthermore, statistical analysis, pattern recognition, and network visualization were 
applied to investigate association of drug efficacy and severe ARs with PGx biomarkers and 
subpopulation. The results indicated that these drugs have a higher association with certain ARs in 
specific patient subpopulations (e.g., a higher association between CYP2D6 poor metabolizers and ARs 
caused by drugs for the treatment of psychiatric disorders), and cover a broad range of therapeutic 
classes (e.g., Psychiatry, Cardiology, Oncology, and Endocrinology). FDALabel database (free publicly 
available) provides a convenient tool to navigate and extract PGx information from FDA-approved drug. 
The knowledge gained from these drugs and biomarkers in this study will enhance the understanding 
of PGx to advance precision medicine. 
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